Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis

BACKGROUND: The Merlin assay for melanoma‐risk assessment has become commercially available to reduce the rate of unnecessary sentinel lymph node biopsies (SLNB) in SLNB‐eligible patients with cutaneous melanoma. Merlin low‐risk patients are recommended to undergo wide local excision (WLE) of the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Thao, Viengneesee, Dholakia, Ruchita, Moriarty, James P., Borah, Bijan J., Dwarkasing, Jvalini, Meves, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098626/
https://www.ncbi.nlm.nih.gov/pubmed/36440797
http://dx.doi.org/10.1111/ijd.16515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098626/
https://www.ncbi.nlm.nih.gov/pubmed/36440797
http://dx.doi.org/10.1111/ijd.16515

Ejemplares similares